Use access key #2 to skip to page content.

June 2011



Word of Caution About KERX

June 29, 2011 – Comments (2) | RELATED TICKERS: KERX

    While checking out Keryx Pharmaceuticals' 10K form, I noticed something that caught my attention. They make the following note under a "Risks" section:  [more]



This Stock is Cliffdiving

June 07, 2011 – Comments (5) | RELATED TICKERS: NBY

     Since NovaBay released results of their Phase II Proof of Concept study with partner Alcon for adenoviral conjunctivitis their shares have fallen 53% ($1.05 from $2.22). Their lead drug candidate NVC-422 failed to meet the primary endpoint of 20% better than placebo, coming in at only 9%. However, the drug performed 15% better than the placebo for epidemic keratoconjunctivitis (EKC), which is considered just as difficult if not more difficult to treat. At Day 11 and 18 blurred vision, a primary concern of patients and the FDA, was successfully treated in 85% and 92% of patients respectively (47% and 42% better than placebo). During the last conference call to discuss results the company stated that NVC-422 acheived "microbiological success", but didn't go into much detail.  [more]

Featured Broker Partners